Joby's 2026 Launch Hinges on FAA Milestones, Not Media Hype

What happened

Joby Aviation's recent media coverage suggests flying taxis could launch in 2026, with early tests in Dubai to gauge customer adoption. However, the DeepValue report reveals that U.S. commercialization depends critically on converting March 2026 FAA-conforming flights into explicit 'for-credit' Type Inspection Authorization activity, a milestone not yet achieved. Company filings admit FAA eVTOL rules are still in flux, posing regulatory risks that could delay timelines beyond optimistic projections. Despite revenue growth from Blade acquisitions, Joby burned $509.9 million in operating cash last year, with no margin of safety at current valuations due to high dilution risks. Investors should therefore focus on upcoming disclosures about FAA testing and eIPP demonstration details to separate real progress from promotional narratives.

Implication

The market's optimism about a 2026 launch is tempered by the DeepValue report's emphasis on unfulfilled FAA milestones, such as 'for-credit' TIA activity, which remains absent in filings. Without this disclosure by year-end, certification delays could trigger the bear case scenario, potentially driving the stock toward $6.50. Early flights in Dubai offer limited validation, as U.S. operations are key, and FAA approval complexities persist, increasing uncertainty. High cash burn and reliance on capital raises amplify dilution pressure, making milestone execution essential to preserve shareholder value. Consequently, adhering to the report's 'WAIT' rating and monitoring for concrete regulatory and operational proofs over the next 6-12 months is prudent to avoid downside risks.

Thesis delta

The new article emphasizes Joby's progress and overseas testing, but it does not address the critical FAA 'for-credit' milestones identified in the DeepValue report as necessary for de-risking the investment. Since the article lacks new information on these fronts, no shift in thesis is warranted; investors should continue to wait for explicit regulatory advancements and eIPP details before reconsidering exposure.